Page 108 - 南京医科大学自然版

第46卷第7期
·1054 · 南 京 医 科 大 学 学 报 2026年7月

及最终版本确认。 sponse and prognosis of immune checkpoint inhibitors ⁃
Author’s Contributions： based combination therapy in advanced hepatocellular
WANG Tian designed the study，performed data analysis， carcinoma using a longitudinal CT⁃based radiomics mod⁃
and drafted the manuscript. XU Zhenggang，WU Huaiyu，and el：a multicenter study［J］. BMC Cancer，2025，25（1）：
CAO Shuya collected and verified the data. JI Guwei conducted 523
statistical analysis and provided revision suggestions. WANG ［10］XU Y，ZHANG M，YANG G，et al. Machine learning
Ke conceived the overall study，reviewed the manuscript，and based radiomic models outperform clinical biomarkers in
approved the final version. predicting outcomes after immunotherapy for hepatocellu⁃
［参考文献］ lar carcinoma［J］. J Hepatol，2025，83（2）：434-446
［11］LI Y，ZHANG Y，FANG Q，et al. Habitat radiomics based
［1］ BRAY F，LAVERSANNE M，SUNG H，et al. Global can⁃
on CT images to predict survival and immune status in he⁃
cer statistics 2022：GLOBOCAN estimates of incidence
patocellular carcinoma，a multi⁃cohort validation study［J］.
and mortality worldwide for 36 cancers in 185 countries［J］.
Acad Radiol，2025，32（5）：2728-2741
CA Cancer J Clin，2024，74（3）：229-263
［12］ZHANG H，ZHANG Z，GAN K，et al. 18F⁃FDG PET/CT⁃
［2］ 国家卫生健康委员会医政医管局. 原发性肝癌诊疗指
based habitat radiomics combining stacking ensemble
南（2024年版）［J］. 临床肝胆病杂志，2024，40（5）：893-
learning for predicting prognosis in hepatocellular carci⁃
918
noma：a multi ⁃ center study［J］. BMC Cancer，2024，24
National Health Commission of the People’s Republic of
（1）：1458
China. Guidelines for diagnosis and treatment of primary ［13］LIU D，LIU F，XIE X，et al. Delta ⁃ radiomics analysis
liver cancer（2024 edition）［J］. Journal of Clinical Hepa⁃ based on multi⁃phase contrast⁃enhanced MRI for predict⁃
tology，2024，40（5）：893-918 ing early recurrence in hepatocellular carcinoma after per⁃
［3］ FINN R S，QIN S，IKEDA M，et al. Atezolizumab plus be⁃ cutaneous thermal ablation［J］. Eur Radiol，2023，33（4）：
vacizumab in unresectable hepatocellular carcinoma［J］. 2514-2525
N Engl J Med，2020，382（20）：1894-1905 ［14］LI M，ZHANG R，ZHANG F，et al. Noninvasive prognos⁃
［4］ CHENG A L，QIN S，IKEDA M，et al. Updated efficacy tic classification of intratumoral heterogeneity in hepato⁃
and safety data from IMbrave150：atezolizumab plus beva⁃ cellular carcinoma with multi ⁃ omics insights and thera⁃
cizumab vs sorafenib for unresectable hepatocellular carci⁃ peutic implications［J］. Sci Adv，2025，11（16）：eads8323
noma［J］. J Hepatol，2022，76（4）：862-873 ［15］SONG H，ZHU L，SUN J，et al. Pretreatment CT⁃based
［5］ QIN S，CHAN S L，GU S，et al. Camrelizumab plus rivoc⁃ machine learning radiomics model predicts response in
eranib versus sorafenib as first⁃line therapy for unresect⁃ unresectable hepatocellular carcinoma treated with lenva⁃
able hepatocellular carcinoma（CARES ⁃ 310）：a ran⁃ tinib plus PD⁃1 inhibitors and interventional therapy［J］.
domised，open⁃label，international phase 3 study［J］. Lan⁃ BMC Cancer，2024，24（1）：1148
cet，2023，402（10408）：1133-1146 ［16］HONG Y M，CHO M，YOON K T，et al. Complications of
［6］ LEWIS S，HECTORS S，TAOULI B. Radiomics of hepato⁃ immunotherapy in advanced hepatocellular carcinoma［J］.
cellular carcinoma［J］. Abdom Radiol（NY），2021，46 Front Oncol，2023，13：1267180
（1）：111-123 ［17］XU Y，SUN S，LIU Q，et al. Impact of immune⁃related ad⁃
［7］ 杨 春，黄 鹏，曾蒙苏.《原发性肝癌诊疗指南 2024 verse events in patients with hepatocellular carcinoma
版》影像学主要更新及亮点解读［J］. 中国临床医学， treated with atezolizumab plus bevacizumab［J］. Hepatol
2024，31（3）：345-352 Commun，2024，8（4）：e0428
YANG C，HUANG P，ZENG M S. Interpretation of main ［18］CLAVIEN P A，BARKUN J，DE OLIVEIRA M L，et al.
imaging updates and highlights in guidelines for diagnosis The Clavien ⁃ Dindo classification of surgical complica⁃
and treatment of primary liver cancer（2024 edition）［J］. tions：five⁃year experience［J］. Ann Surg，2009，250（2）：
Chinese Journal of Clinical Medicine，2024，31（3）：345- 187-196
352 ［19］JUNG J，WOO S，KIM H S，et al. Machine learning⁃based
［8］ WANG Y，WEI R，LIU G，et al. Predicting early recur⁃ clinical decision support system for treatment recommen⁃
rence of hepatocellular carcinoma after thermal ablation dation and overall survival prediction of hepatocellular
based on longitudinal MRI with a deep learning ap⁃ carcinoma：a multi ⁃ center study［J］. NPJ Digit Med，
proach［J］. Oncologist，2025，30（3）：oyaf013 2024，7（1）：34
［9］ HUANG K，GUO L，DAI J，et al. Predicting treatment re⁃ （下转第1063页）